<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998604</url>
  </required_header>
  <id_info>
    <org_study_id>LPS16747</org_study_id>
    <secondary_id>2021-000829-27</secondary_id>
    <secondary_id>U1111-1255-4713</secondary_id>
    <nct_id>NCT04998604</nct_id>
  </id_info>
  <brief_title>EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients</brief_title>
  <acronym>EVEREST</acronym>
  <official_title>A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective&#xD;
&#xD;
      -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and&#xD;
      improving sense of smell&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  To evaluate the efficacy of dupilumab in improving CRSwNP symptoms at Week 24 compared&#xD;
           to omalizumab&#xD;
&#xD;
        -  To evaluate the efficacy of dupilumab in improving lung function at Week 24 compared to&#xD;
           omalizumab&#xD;
&#xD;
        -  To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at&#xD;
           Week 24 compared to omalizumab&#xD;
&#xD;
        -  To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24&#xD;
           compared to omalizumab&#xD;
&#xD;
        -  To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week&#xD;
           24 compared to omalizumab&#xD;
&#xD;
        -  To evaluate the effect of dupilumab on CRSwNP overall disease severity at Week 24&#xD;
           compared to omalizumab&#xD;
&#xD;
        -  To evaluate the effect of dupilumab on asthma control at Week 24 compared to omalizumab&#xD;
&#xD;
        -  To evaluate the safety of dupilumab and omalizumab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant will be 40 weeks. The study will comprise 3 periods: up to 4&#xD;
      weeks screening and run-in period; 24 weeks Randomized investigational medicinal product&#xD;
      (IMP) intervention period; up to 12 weeks follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">February 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo injections will be administered as needed to blind the number of active dupilumab and omalizumab injections</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 24 in Nasal Polyp Score (NPS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The total nasal polyps score (NPS) is the sum of the right and left nostrils, ranging from 0 (no polyps) to 8 (large polyps causing complete obstruction).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Week 24 in University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The UPSIT score ranges from 0 to 40, with 40 being the best possible score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in the loss of smell score of the CRSwNP Nasal Symptom Diary</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Loss of smell scores are scored from 0 ('No symptoms') to 3 ('Severe symptoms').</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in the nasal congestion (NC) score of the CRSwNP Nasal Symptom Diary</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>NC scores are scored from 0 ('No symptoms') to 3 ('Severe symptoms').</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in pre-bronchodilator forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Pre-bronchodilator forced expiratory volume in 1 second (volume of air in liters).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in Total Symptom Score (TSS) derived from the CRSwNP Nasal Symptom Diary</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>TSS ranges from 0 to 9. Higher scores on the TSS indicate greater symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in 22-Item Sino-nasal Outcome Test (SNOT-22) and</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>SNOT-22 is a patient-reported outcome (PRO) questionnaire. Score ranges from 0 to 110 with higher score indicating greater rhinosinusitis related health burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in SNOT-22 nasal domain score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>SNOT-22 is a patient-reported outcome (PRO) questionnaire. Nasal domain score ranges from 0-40 with high score representing higher disease burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in Nasal Peak Inspiratory Flow (NPIF)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Nasal Peak Inspiratory flow (nasal flow in liter per minute).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in rhinosinusitis visual analogue scale (VAS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Severity of the rhinosinusitis from 0 to 10. Higher scores indicate more severe symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in 7-item Asthma Control Questionnaire (ACQ-7)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Asthma control with 6 questions plus FEV1 measure. Score ranges from 0 (totally controlled) and 6 (severely uncontrolled). Higher score indicates lower asthma control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of special interest (AESIs)</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Incidence of adverse events of special interest (AESIs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">422</enrollment>
  <condition>Chronic Rhinosinusitis With Nasal Polyps</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing every 2 weeks (Q2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Q2W or every 4 weeks (Q4W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>solution for injection subcutaneous</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <other_name>SAR231893 Dupixent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>solution for injection subcutaneous</description>
    <arm_group_label>Omalizumab</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>solution for injection subcutaneous</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_label>Omalizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be at least 18 (or the legal age of consent in the jurisdiction in&#xD;
             which the study is taking place) years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants with bilateral sino-nasal polyposis, that despite prior treatment with&#xD;
             Systemic corticosteroids (SCS) anytime within the past 2 years; and/or medical&#xD;
             contraindication/intolerance to SCS; and/or prior surgery for NP have:&#xD;
&#xD;
               -  An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a&#xD;
                  minimum score of 2 in each nasal cavity) at visit 1; AND&#xD;
&#xD;
               -  Ongoing symptoms of Nasal congestion/blockade/obstruction and loss of smell for&#xD;
                  at least 8 weeks before screening (Visit 1), AND&#xD;
&#xD;
               -  Nasal congestion/blockade/obstruction and a weekly average severity greater than&#xD;
                  1 at randomization (Visit 2) AND&#xD;
&#xD;
               -  loss of smell symptom severity score 2 or 3 at screening (Visit 1) and a weekly&#xD;
                  average severity of greater than 1 at time of randomization (Visit 2).&#xD;
&#xD;
          -  Participants with a physician diagnosis of asthma based on the Global Initiative for&#xD;
             Asthma (GINA) 2020 for ≥12 months treated with low, medium or high dose inhaled&#xD;
             corticosteroids (ICS) and a second controller (ie, LABA), a third controller is&#xD;
             allowed but not mandatory. The dose regimen should be stable for at least 1 month&#xD;
             before Visit 1 (screening visit) and during the screening and run-in period.&#xD;
&#xD;
          -  Pre-bronchodilator FEV1 ≤85% of predicted normal at Visit 1 (screening visit) and&#xD;
             Visit 2, prior to randomization.&#xD;
&#xD;
          -  Asthma Control Questionnaire 5-question version (ACQ-5) score ≥1.5 at Visits 1 and 2.&#xD;
&#xD;
          -  Treatment with intranasal mometasone ≥200 μg once daily (QD) (or equivalent of another&#xD;
             INCS) for 1 month prior to Visit 1 and during the run-in period (for CRSwNP).&#xD;
&#xD;
          -  Eligibility as per omalizumab drug-dosing table (serum IgE level ≥30 to ≤1500 IU/mL&#xD;
             and body weight ≥30 to ≤150 kg) and ability to be dosed per the dosing table.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          -  Participants who have undergone any sinus intranasal surgery (including polypectomy)&#xD;
             within 6 months before Visit 1.&#xD;
&#xD;
          -  Participants who have had a sino-nasal surgery changing the lateral wall structure of&#xD;
             the nose, making impossible the evaluation of NPS.&#xD;
&#xD;
          -  Participants with conditions/concomitant diseases making them non evaluable at Visit 1&#xD;
             or for the primary efficacy endpoint such as: Antrochoanal polyps, Nasal septal&#xD;
             deviation that would occlude at least one nostril, Acute sinusitis, nasal infection,&#xD;
             or upper respiratory infection.&#xD;
&#xD;
          -  Severe asthma exacerbation requiring treatment with SCS in the last 4 weeks prior to&#xD;
             Visit 1 and during screening.&#xD;
&#xD;
          -  Severe concomitant illness(es) that, in the Investigator's judgment, would adversely&#xD;
             affect the participant's participation in the study&#xD;
&#xD;
          -  Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use&#xD;
             of antiparasitic drugs within 2 weeks before Visit 1 (screening visit) or during the&#xD;
             screening and run-in period.&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology&#xD;
             at Visit 1 (screening visit).&#xD;
&#xD;
          -  Known or suspected immunodeficiency, including history of invasive opportunistic&#xD;
             infections&#xD;
&#xD;
          -  Active malignancy or history of malignancy within 5 years before Visit 1 (screening&#xD;
             visit), except completely treated in situ carcinoma of the cervix and completely&#xD;
             treated and resolved non metastatic squamous or basal cell carcinoma of the skin.&#xD;
&#xD;
          -  History of systemic hypersensitivity or anaphylaxis to dupilumab and omalizumab,&#xD;
             including any excipient&#xD;
&#xD;
          -  Treatment with a live (attenuated) vaccine within 4 weeks before Visit 1 (screening&#xD;
             visit).&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :8400017</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 28, 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

